Pérez-García, J. M., Cortés, J., Ruiz-Borrego, M., Colleoni, M., Stradella, A., Bermejo, B., . . . Llombart-Cussac, A. (2024). 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): A randomised, open-label, phase 2 trial. The Lancet, 403(10437), 1649-1659. https://doi.org/10.1016/S0140-6736(24)00054-0

Pérez-García, José Manuel, et al. "3-year Invasive Disease-free Survival with Chemotherapy De-escalation Using an 18F-FDG-PET-based, Pathological Complete Response-adapted Strategy in HER2-positive Early Breast Cancer (PHERGain): A Randomised, Open-label, Phase 2 Trial." The Lancet 403, no. 10437 (2024): 1649-1659. https://doi.org/10.1016/S0140-6736(24)00054-0.

Pérez-García, José Manuel, et al. "3-year Invasive Disease-free Survival with Chemotherapy De-escalation Using an 18F-FDG-PET-based, Pathological Complete Response-adapted Strategy in HER2-positive Early Breast Cancer (PHERGain): A Randomised, Open-label, Phase 2 Trial." The Lancet, vol. 403, no. 10437, 2024, pp. 1649-1659, https://doi.org/10.1016/S0140-6736(24)00054-0.